Interleukin 21: combination strategies for cancer therapy

被引：77

作者：

Skak, Kresten ^{[2
]}

Kragh, Michael ^{[3
]}

Hausman, Diana ^{[4
]}

Smyth, Mark J. ^{[1
]}

Sivakumar, Pallavur V.

机构：

[1] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 8006, Australia

[2] Novo Nordisk AS, Canc Pharmacol, DK-2760 Malov, Denmark

[3] Maxygen, Vivo Pharmacol, DK-2970 Horsholm, Denmark

[4] Zymogenet Inc, Dept Clin Res, Seattle, WA 98102 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2008年 / 7卷 / 03期

关键词：

D O I：

10.1038/nrd2482

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In the past 20 years researchers have attempted to activate the host immune defence system to kill tumour cells and eradicate cancer. In some cases, the response of patients to immunotherapy has been extremely successful; however, other trials have shown disappointing results, and so there is a clear need for more effective therapies that can effectively adjunct conventional approaches. Interleukin 21 ( IL21) is a new immune-stimulating cytokine that has demonstrated antitumour activity in several preclinical models, and has recently undergone Phase I trials in metastatic melanoma and renal cell carcinoma. Here, we provide an overview of the antitumour effects of IL21 and describe strategies to combine IL21 with other drugs for future cancer therapies.

引用

页码：231 / 240

页数：10

共 132 条

[1] IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells [J].

Alves, NL ;

Arosa, FA ;

van Lier, RAW .

JOURNAL OF IMMUNOLOGY, 2005, 175 (02) :755-762

[2] Recent developments in colorectal cancer treatment by monoclonal antibodies [J].

Arsene, Dominique ;

Galais, Marie-Pierre ;

Bouhier-Leporrier, Karine ;

Reimund, Jean-Marie .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (11) :1175-1192

[3]

Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185

[4] Update on the role of interleukin 2 and other cytokines in the treatment of patients with Stage IV renal carcinoma [J].

Atkins, MB ;

Regan, M ;

McDermott, D .

CLINICAL CANCER RESEARCH, 2004, 10 (18) :6342S-6346S

[5]

ATKINS MB, 2000, CANC J SCI AM SUPPL, V1, P11

[6] Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents [J].

Barrett, A. J. ;

Savani, B. N. .

LEUKEMIA, 2006, 20 (10) :1661-1672

[7] Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment [J].

Barrett, John .

CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (05) :592-598

[8] Regulatory T cells in cancer [J].

Beyer, Marc ;

Schultze, Joachim L. .

BLOOD, 2006, 108 (03) :804-811

[9] Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery [J].

Bolesta, Elizabeth ;

Kowalczyk, Aleksandra ;

Wierzbicki, Andrzej ;

Eppolito, Cheryl ;

Kaneko, Yutaro ;

Takiguchi, Masafumi ;

Stamatatos, Leonidas ;

Shrikant, Protul A. ;

Kozbor, Danuta .

JOURNAL OF IMMUNOLOGY, 2006, 177 (01) :177-191

[10] IL-21 induces the functional maturation of murine NK cells [J].

Brady, J ;

Hayakawa, Y ;

Smyth, MJ ;

Nutt, SL .

JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2048-2058

← 1 2 3 4 5 6 7 8 9 10 →